Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05041127 · ClinicalTrials.gov registry record · Phase 2
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
A Phase 2 study of Chordoma and Metastatic Chordoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT05041127 is a Phase 2 study of Chordoma and Metastatic Chordoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants, below the 85-participant average among 15 other Chordoma trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05041127, a Phase 2 study of Chordoma and Metastatic Chordoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target patient population will be any chordoma patient 18 years of age with locally unresectable disease or metastatic disease.
Conditions Studied
Interventions
- BIOLOGICAL Cetuximab
- OTHER Questionnaire Administration
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05041127
The ClinicalTrials.gov registry entry for NCT05041127 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 15 other Chordoma trials with a reported enrollment target (66% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chordoma appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT05041127 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05041127 about?
NCT05041127 is a clinical study titled "Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma". This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target patient population will be any chordoma patient 18 years of age with locally unresectable disease or metastatic dis...
What is the current status of trial NCT05041127?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2022-05-27. Estimated completion is 2026-09-01.
What conditions does trial NCT05041127 study?
This clinical trial studies the following conditions: Chordoma, Metastatic Chordoma, Unresectable Chordoma.
What interventions are being tested in trial NCT05041127?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT05041127?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05041127 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab and Pemetrexed for Progressive Chordoma
RECRUITING · Phase 2
-
Proton Beam Therapy for Chordoma Patients
ACTIVE NOT RECRUITING · Phase 2
-
Children and Adults With Chordoma
RECRUITING
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.